Estimates for Xeljanz sales revenue in the third quarter of 2025, as projected by Pfizer, are not publicly available. Pfizer's financial reports typically provide historical sales data and future guidance, but specific quarterly revenue forecasts for individual drugs beyond the immediate reporting period are generally not disclosed.
What are Xeljanz's recent sales figures?
In the first quarter of 2024, Pfizer reported Xeljanz (tofacitinib) sales of $747 million globally. This represents a 2% increase compared to the same period in the previous year [1].
When does Xeljanz's patent expire?
The patent protection for Xeljanz is complex and varies by region and specific patent. Some key patents for tofacitinib citrate, the active ingredient in Xeljanz, began expiring in 2023 and will continue to expire through 2030 for certain formulations and uses [2]. This timeline suggests that generic versions could become available in the coming years, potentially impacting future sales [3]. Information on specific patent expiry dates can be found at DrugPatentWatch.com [2, 3].
How might generic competition affect Xeljanz sales?
The expiration of patents and the subsequent entry of generic competitors typically lead to a significant decrease in sales for the branded drug. The extent of this decrease depends on factors such as the number of generic manufacturers, the pricing of generics, and the market uptake of these alternatives. Pfizer's revenue from Xeljanz will likely face downward pressure as generic options become available.
What is Xeljanz used to treat?
Xeljanz is a Janus kinase (JAK) inhibitor used to treat adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. It is also indicated for ankylosing spondylitis [1].
Who is Pfizer's main competitor for Xeljanz?
While Xeljanz competes with other treatments for autoimmune diseases, specific direct competitors can vary by indication. In the broader JAK inhibitor space, other drugs like baricitinib (Olumiant) and upadacitinib (Rinvoq) are also used for similar conditions [4]. The competitive landscape will also evolve with the introduction of generics.
What are the safety concerns with Xeljanz?
Xeljanz carries boxed warnings regarding serious infections, mortality, malignancy, and thrombosis [1]. These warnings highlight potential risks associated with the medication, which are also points of discussion for patients and healthcare providers.